Peptide bioregulators
Vesugen
Organ-targeted peptide supporting vascular endothelial cell function and tissue regeneration.
Approved in Russia; PubMed-indexed research available Peptide bioregulators Longevity
- Full name
- Vesugen (vascular-tissue-targeted peptide bioregulator, Lys-Glu-Asp / KED)
- Also known as
- KED peptide
- Regulatory status
- Approved in Russia; PubMed-indexed research available
Origin
Developed by the St. Petersburg Institute of Bioregulation and Gerontology as a vascular-targeted bioregulator. The tripeptide Lys-Glu-Asp (KED) was synthesized within the organ-targeted peptide tradition.
Mechanism
Activates proliferation and renewal in vascular endothelial cells (increasing Ki-67, reducing p53), normalizes endothelin-1 expression in atherosclerotic endothelium, and increases SIRT1 expression involved in DNA repair.
Research summary
Evidence
A 2016 paper described molecular mechanisms of vasoprotection including endothelin-1 normalization; a 2014 paper showed the KED tripeptide reduces adhesion molecules involved in atherosclerotic plaque formation. Other studies document effects on endothelial proliferation and erectile function in elderly men with atherosclerosis. Research base is small, a handful of PubMed-indexed studies, primarily from Russian institutions, with limited independent Western replication.
Evidence tier: Approved in Russia; PubMed-indexed research available — see the methodology note for how this is assessed.
Citations
- Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis — Khavinson et al. 2016
- Molecular aspects of anti-atherosclerotic effects of short peptides — Khavinson et al. 2014
Reported benefits
- vascular endothelial cell regeneration (preclinical)
- claimed improved blood flow/circulation
- claimed reduced atherosclerotic plaque formation
- claimed improved erectile function in atherosclerosis-related ED
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Subcutaneous injection | Community reports: 10-20 mg daily or every other day for 10-20 days, repeated every 3-6 months. |
Side effects
- generally well tolerated
- localized injection-site reactions possible
- one study noted prooxidant activity in a chemiluminescence assay
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Discussed in longevity communities for cardiovascular support, sometimes combined with other vascular-support peptides; entirely anecdotal.